Business Wire

ESI Group and the DesCartes Program Aiming at Transforming Singapore Into a Hybrid, Ethical and Sustainable Smart Nation

25.1.2022 10:00:00 EET | Business Wire | Press release

Share

Regulatory News:

ESI Group, Rungis, France, (ISIN Code: FR0004110310, Mnemo: ESI), a global player in virtual prototyping for industries, is collaborating in the launch of the DesCartes project in Singapore by providing its scientists, its expertise in hybridization methods and its virtual prototyping software solutions to the various stakeholders.

DesCartes a 5-year and a 35 million euros budget collaborative program, has been selected by the National Research Foundation (NRF) of Singapore and is based on the CREATE campus, "Campus for research excellence and technological enterprise", the international research hub of Singapore. Behind this very French name lies one of the largest collaborative programs of the CNRS: the "Program on Intelligent Modelling for Decision-making in Critical Urban Systems", dedicated to Hybrid Artificial Intelligence.

A smart city project to a better extent: A smart nation project

For many years, many smart cities projects have been launched. The principle of these smart cities is to collect data generated by sensors, to deploy specific applications, such as sensors indicating air pollution, alerts on accidents, traffic conditions in real time... However, the concept of smart nation carried by Singapore differs from the others because it pushes the concept to its paroxysm: from the digitization of an entity, a building, a single system to the digitization of a whole city interacting in real time.

From electrical grid optimization to delivery drones

DesCartes is developing hybrid AI methods, combining AI with knowledge-based models (physics, engineering), to enable trusted, real-time decision-making that is "people-centric" and "in harmony with society." All in response to complex situations related to critical urban systems in the context of Singapore's "Smart Nation." This research will be applied, for example, to urban mobility or energy management, or to anticipate the needs of future transportation networks, smart industries, or smart buildings. "For example, we aim to develop solutions to optimize the supply and demand of the electricity network, or solutions to improve the flow of cab drones or delivery drones, or to develop intelligent predictive maintenance applied to industrial tools," explains Dominique Baillargeat, director of CNRS@CREATE. Systems in the city that will be able to analyze data on the use of services by the population and then make optimization decisions.

ESI's role in this project.

ESI, recognized worldwide for its predictive physics modeling and virtual prototyping expertise, will play several roles in this program. First, its Scientific Director, also a member of CNRS and ENSAM, Prof. Francisco Chinesta, will be the program director. In addition, the Group will make its performance simulation solutions (VPS, VA One, Simulation X, etc.) and its expertise in hybridization and model reduction methods available to the partners and the program. ESI will thus be able to predict material behavior in real time, anticipate incidents (associated with damage, cracks, corrosion, etc.), model the wind for better use of drones, and make city management more intelligent and human-friendly. Finally, ESI will bring all its engineering expertise to optimize the platform in which the data will be used to make the right decision at the right time.

Dr. Francisco Chinesta, leader of the engineering activity for ESI in this project, says: "The goal of the Singapore program is to think and design an interconnected smart city with features that will revolutionize the concept of smart cities. In this project, it is essential to place the citizen - the human, but also more generally the living - at the heart of the hybridization devices. All the partners in this project aim to make Singapore an ethical, responsible and secure new city."

The Descartes program partners

The Descartes project involves on the French side:

  • CNRS
  • 13 universities and prestigious schools : Université Paris-Saclay, Université Toulouse Paul Sabatier, Université Lyon III Jean Moulin, Université de Bordeaux, École Nationale de l'Aviation Civile, Université Paris Sciences & Lettres, Université de Strasbourg, Arts et Métiers, INP Grenoble, INP ENSEEIHT, Ecole Normale Supérieure de Paris-Saclay, Université Grenoble-Alpes, Université Côte-d'Azur.

and, on the Singaporean side:

  • 3 universities: Nanyang Technology University, National University of Singapore, Singapore University of Technology and Design.
  • A*STAR: Agency for Science, Technology and Research. A*STAR is the national R&D agency of Singapore.

It is developed in collaboration with five industrial partners: ARIA, CETIM MATCOR, EDF, ESI Group and Thales.

About ESI Group

Founded in 1973, ESI Group is a leading innovator in Virtual Prototyping solutions and a global enabler of industrial transformation. Thanks to the company’s unique know-how in the physics of materials, it has developed and refined, over the last 45 years, advanced simulation capabilities. Having identified gaps in the traditional approach to Product Lifecycle Management (PLM), ESI has introduced a holistic methodology centered on industrial productivity and product performance throughout its entire lifecycle, i.e. Product Performance Lifecycle™, from engineering to manufacturing and in operation. Present in more than 20 countries, and in major industrial sectors, ESI employs 1200 high level specialists around the world and reported 2020 sales of €132.6 million. ESI is headquartered in France and is listed on compartment B of Euronext Paris.

For further information, go to www.esi-group.com.

Follow ESI:  LinkedInFacebookTwitterYouTube

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

ESI - Press & Shareholders
Florence Barré
investors@esi-group.com
+33 1 49 78 28 28

Verbatee – Press & Investors Relations
Jérôme Goaer, j.goaer@verbatee.com, +33 6 61 61 79 34
Aline Besselièvre, a.besselievre@verbatee.com, +33 6 61 85 10 05

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 08:30:00 EEST | Press release

SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye